Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome.
about
ClC-2 regulation of intestinal barrier function: Translation of basic science to therapeutic targetChemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging TreatmentsElobixibat and its potential role in chronic idiopathic constipationConstipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies.Effects of lubiprostone on pacemaker activity of interstitial cells of cajal from the mouse colon.Contrasting effects of linaclotide and lubiprostone on restitution of epithelial cell barrier properties and cellular homeostasis after exposure to cell stressors.American Gastroenterological Association technical review on constipation.Metabolic and toxicological considerations for the latest drugs used to treat irritable bowel syndrome.Lubiprostone vs Senna in postoperative orthopedic surgery patients with opioid-induced constipation: a double-blind, active-comparator trial.Irritable bowel syndrome: the evolution of multi-dimensional looking and multidisciplinary treatmentsA comparison of linaclotide and lubiprostone dosing regimens on ion transport responses in human colonic mucosaResting anal pressure, not outlet obstruction or transit, predicts healthcare utilization in chronic constipation: a retrospective cohort analysis.Drug development for the irritable bowel syndrome: current challenges and future perspectivesComprehensive self-management reduces the negative impact of irritable bowel syndrome symptoms on sexual functioningSafety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome.Constella™(EU)-Linzess™(USA): the last milestone in the long journey of the peptide linaclotide and its implications for the future of peptide drugs.Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndrome.New Options in Constipation Management.Opioid-Related Constipation in Patients With Non-cancer Pain Syndromes: a Review of Evidence-Based Therapies and Justification for a Change in Nomenclature.Irritable bowel syndrome in women.The cannabinoid-1 receptor inverse agonist taranabant reduces abdominal pain and increases intestinal transit in mice.Plecanatide: a new guanylate cyclase agonist for the treatment of chronic idiopathic constipation.
P2860
Q28066092-C32A06CD-7050-4416-A3DB-0507038BF641Q28079705-78A99E1F-3EBD-4628-88D2-A566A382D516Q28244603-4C2A8215-0326-498A-8F94-639AD29D1343Q33958710-442B8CD6-1A62-49D7-84BC-DD4BBBB9D2EDQ34097910-0A687A0E-74C9-42FA-A13B-0E28FD079EB1Q34254749-F4CEECC6-76F5-4257-982E-8ADB8986DDF7Q34319119-ADEBAF27-A649-40F5-85D7-74908F758747Q34323319-A317B901-0A9C-4E57-8EE5-059B8A38B7CDQ34552212-C28442FF-0955-465D-86F9-2BD12661B381Q34660338-AA762B42-9733-464B-8BA7-F6E44096C011Q35664952-7AE33F2A-F2AF-4187-A239-577395AB6C95Q36096138-77C74402-97D5-457C-9CEC-346219762020Q36579818-2398744A-739A-4FCD-806F-F5EF3DC58D27Q36961142-38F28C6A-9BD9-41DD-B83A-5D72FCDE8CD9Q38029718-705709EF-2B06-4552-B602-0FF0D9FC4DACQ38086870-731623CD-ED86-4B7D-8487-CDAC3564AC1BQ38175457-309BF56B-7B89-4698-B813-9C87347FB7E0Q38602701-92A3E0EA-CEF4-4729-B6EF-F8D78F3DEA7DQ38880480-ED40D266-6C73-4A29-8C0D-8D7BCC2D3F7DQ48325807-0E321A9F-2DD8-4C94-9AE7-0193EF90E43EQ50975152-CDCEC2E1-FF9C-447B-920D-C4B04F2A2525Q55259850-44FFB9E6-6295-4331-AD02-68D94F350955
P2860
Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome.
@en
Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome.
@nl
type
label
Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome.
@en
Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome.
@nl
prefLabel
Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome.
@en
Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome.
@nl
P2860
P1476
Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome.
@en
P2093
Satish S C Rao
P2860
P2888
P304
P356
10.1007/S10620-011-1702-2
P577
2011-04-27T00:00:00Z